Bifogade filer
CombiGene PM 24032020 Learning And Memory Study EN
CombiGene David Woldbye
CombiGene Karin Agerman
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
CombiGene has recently concluded a successful learning and memory study in the CG01 epilepsy project. The outcome of the study is very gratifying and shows that NPY and Y2, the active substances in CG01, have no significant negative effect on cognitive functions.
No negative effect on cognitive function
NPY, one of the active substances in CG01, is associated with several physiological processes in the body, among others, memory and learning. CombiGene has therefore received an inquiry from the FDA and the Swedish Medical Products Agency as to whether CG01 has any impact on cognitive functions. The concluded learning and memory study answers that important question: increased expression of NPY and Y2 has no negative effect on memory or learning functions in the experimental model used in the study.
David Woldbye, one of CombiGene’s scientific founders, commented on the results of the study. “The results of earlier academic studies on the effect of NPY on memory and learning have been contradictory. It is therefore especially pleasing to note that we can now demonstrate that we do not affect memory and learning when we inject CG01 into one of the brain’s two hippocampi, precisely as we intend to do in humans.”
Karin Agerman, CombiGene’s Chief Research and Development Officer, is also very satisfied with the outcomes of this study and the recently published pharmacokinetic study. “With the completion of the memory study it is very reassuring to have successfully answered several questions from the FDA and the Swedish Medical Products Agency. This brings us one step closer to start the first study in humans. More and more pieces in the CG01 project are now falling into place.”